Market Analysis: Global Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis Market is expected to rise gradually to an estimated value of USD 157.13 million by 2026, registering a CAGR of 3.7% in the forecast period of 2019-2026 with the annual sales of USD 117.5 million in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.
Market Definition: Global Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic disease of the liver which is characterized by progressive inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts. It is progressive in most patients and leads to cirrhosis.
According to a study of NCBI, there were approximately 0.2 - 1.2 million people having primary sclerosing cholangitis as of 2018, in Northern European countries and North America where the disease is most common, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.
Get More Insights About Global Primary Sclerosing Cholangitis Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-sclerosing-cholangitis-market
Rise in incidence and prevalence rate of liver failure and bile cancer associated with PSC.
Large No. of pipeline molecules is expected to drive the growth of the market.
Withdrawal of novel molecules from late-stage clinical trials will restrain the growth of the market.
Organ transplantation remains the alternative which is associated with many risk factors like relapse of the disease.
Lack of skilled expertise in remote areas
Fewer Government initiatives taken in this direction.
Segmentation: Global Primary Sclerosing Cholangitis Market
PSC associated with autoimmune hepatitis
By Treatment Type
By Symptom Control
By End- User
Rest of South America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
United Arab Emirates
Rest of Middle East & Africa
Know more about this report https://www.databridgemarketresearch.com/reports/global-primary-sclerosing-cholangitis-market
Key Developments in the Market:
On 19th January, 2016, Acorda Therapeutics, Inc. announced that it entered into an agreement to acquire Biotie Therapies Corp. According to the agreement, the company will acquire the four pipeline products that include BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC) which will help company to grow.
On 27th March, 2019, Gilead Sciences, Inc. announced the company’s research and development programs in primary sclerosing cholangitis (PSC) will be presented at The International Liver Congress™ 2019 in Vienna. Currently the novel molecule, Cilofexor has not get the approval but once it gets approval it will generate the revenue for the company and contribute towards the growth of the market.
Competitive Analysis: Global Primary Sclerosing Cholangitis Market
Global primary sclerosing cholangitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of primary sclerosing cholangitis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Competitors: Global Primary Sclerosing Cholangitis Market
Few of the major competitors currently working in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals, Inc. (US), Dr. Falk Pharma GmbH (Germany), ALLERGAN (Ireland), Takeda Pharmaceutical Company Limited. (Japan), DURECT CORPORATION (US), Conatus Pharmaceuticals, Inc. (US), Sirnaomics, Inc. (US), and HighTide Therapeutics Inc. (China), Glenmark (India), Impax Laboratories, LLC (US), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (Israel) and few among others.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-primary-sclerosing-cholangitis-market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market